In a real-life setting, direct-acting antivirals to people who inject drugs with chronic hepatitis C in Turkey
The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology(2021)
摘要
Introduction: People who inject drugs (PWID) should be treated in order
to eliminate hepatitis C virus (HCV) in the world. Aims: The aim of this
study was to compare direct acting antivirals (DAAs) treatment of HCV
for PWID and non-PWID in real life setting. Materials and methods: We
performed a prospective, non-randomized, observational multi-center
cohort study in 37 centers. All patients treated with DAAs therapy
between April 1, 2017 to February 28, 2019 were included. In total,
2,713 patients were included in the study among which 250 were PWID and
2,463 were non-PWID. Besides patient characteristics, treatment
response, follow-up and side effects of treatment were also analyzed.
Results: Genotype 1a and 3 were more prevalent in PWID infected patients
(20.4% vs 9.9% and 46.8% vs 5.3%). The number of naïve patients was
higher in PWID (90.7% vs 60.0%), while the number of patients with
cirrhosis was higher in non-PWID (14.1% vs 3.7%). The loss of follow
up was higher in PWID (29.6% vs 13.6%). There was no difference in the
sustained virologic response at 12 weeks after treatment (98.3% vs
98.4%), but the end of treatment response was lower in PWID (96.2% vs
99.0%). In addition, the rate of treatment completion was lower in PWID
(74% vs 94.4%). Conclusion: DAAs were safe and effective in PWID.
Primary measures should be taken to prevent the loss of follow-up and
poor adherence in PWID patients in order to achieve World Health
Organization’s objective of eliminating viral hepatitis.
更多查看译文
关键词
Drug therapy,drug users,hepatitis C virus
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要